Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals Misses on EPS, Stock Down 1.98%

Supernus Pharmaceuticals reported an EPS that fell short of expectations, leading to a slight decline in stock price. The lack of revenue data and guidance updates may raise concerns among investors about the company's near-term performance. The stock reaction reflects cautious sentiment as investors assess the implications of the earnings report.